From being one of the first pharmaceutical companies with a chlorofluorocarbon (CFC)-free beclometasone dipropionate (BDP) treatment, to our ambitious investments in future respiratory innovations,1,2 we know action is needed to protect our planet – but not at the expense of the very best care for people with respiratory diseases.
At Chiesi, we believe true ‘sustainability’ can only be achieved with a broad array of projects that protect both patients and the planet. This holistic approach is key – and means we sometimes see things a little differently than other pharmaceutical companies.
We strive to consider every aspect of the long-term future of respiratory care for patients, healthcare professionals (HCPs) and the planet, for example:
Our approach to sustainability may surprise you.
BDP: Beclometasone dipropionate; CFC: Chlorofluorocarbon; DPI: Dry powder inhaler; HFA: Hydrofluoroalkane; pMDI: Pressurised metered dose inhalers.